8-K: electroCore Reports Q1 2026 Record Revenue, Reaffirms Guidance

electroCore announced record first quarter 2026 net sales of $9.6 million, a 43% increase year-over-year, and reaffirmed its full-year revenue growth guidance of 30%.

Summary

• electroCore reported record first quarter 2026 net sales of $9.6 million, a 43% increase compared to $6.7 million in the first quarter of 2025.
• The company experienced a net loss of $5.3 million for the quarter, but its Adjusted EBITDA net loss improved by 24% year-over-year to $2.3 million.
• Full-year 2026 revenue guidance remains at approximately 30% annual growth over 2025.
• Growth drivers include increased prescription sales of gammaCore within the U.S. Department of Veterans Affairs (VA) and direct-to-consumer Truvaga sales.
• The Quell Fibromyalgia franchise, acquired in May 2025, also contributed over $1.0 million in quarterly revenue for the first time.
• Truvaga expanded internationally with a launch in the United Kingdom in January 2026 and showed improved marketing efficiency with a Return on Advertising Spend (ROAS) of approximately 2.37x.
• The company is preparing to launch Quell Relief for lower extremity pain in the second half of 2026 and is developing a next-generation mobile app.
• Michael Fox joined as Chief Operating Officer in April 2026 to accelerate revenue growth.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to record revenue, strong gross margins, and reaffirmed guidance, despite a GAAP net loss that was impacted by one-time expenses.

Positives

• Record quarterly revenue of $9.6 million, up 43% year-over-year.
• Gross profit margin expanded to 87% for the quarter.
• Adjusted EBITDA net loss improved by 24% year-over-year to $2.3 million.
• Reaffirmed full-year 2026 revenue guidance of approximately 30% annual growth.
• VA channel continues to drive prescription growth, with gammaCore revenue up 26% year-over-year.
• Quell product line surpassed $1.0 million in quarterly revenue for the first time.
• Truvaga revenue grew 38% year-over-year to $1.5 million, with improved marketing efficiency (ROAS of 2.37x).
• International expansion of Truvaga with a launch in the UK.

Negatives

• Reported a GAAP net loss of $5.3 million for the quarter, an increase from $3.9 million in Q1 2025.
• Net loss per share was $0.59, compared to $0.47 in the prior year period.
• Total cash, cash equivalents, and marketable securities decreased to $8.8 million at March 31, 2026, from $11.6 million at December 31, 2025.
• Selling, general and administrative expenses increased significantly to $12.9 million from $8.9 million, driven by leadership transition expenses and legal fees.
• Total liabilities increased to $21.2 million from $20.4 million.
• Stockholders deficit increased to $(5.7) million from $(1.7) million.

Risks

• The company may not be able to raise the additional funding needed to continue its business and product development plans.
• There are inherent uncertainties associated with developing new products or technologies.
• The ability to commercialize gammaCore, TAC-STIM, Truvaga, and Quell is subject to market acceptance and regulatory factors.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.
• The impact of an ongoing leadership and management transition could affect operations.
• Competition in the industry and overall economic and market conditions pose risks.
• The company's ability to continue as a going concern is mentioned as a forward-looking statement, implying potential financial instability.
• Legal fees related to ongoing litigation are impacting general and administrative expenses.

Future Outlook

The Company is reaffirming its full-year 2026 revenue guidance of approximately 30% annual growth over full-year 2025. The company expects the majority of fiscal year 2026 revenue to continue to come from the VA. The company expects to launch Quell Relief for lower extremity pain later in the second half of 2026 and is developing a next-generation mobile application.

Management Comments

• "Our first quarter results reflect what we believe is a meaningful inflection point for electroCore," said Joshua Lev, Interim President and Chief Financial Officer.
• "Quarterly revenue of $9.6 million was our highest ever and was accomplished with 87% gross profit margin."
• "Joining electroCore at this stage of the Company's growth was a clear opportunity. The platform is generating meaningful revenue with gross margins that compare favorably to many medical device peers, and the operating leverage opportunity is substantial. My focus will be on scaling our commercial organization efficiently - ensuring that incremental revenue translates into bottom-line improvement.", said Michael Fox, Chief Operating Officer.

Industry Context

StockSavvy.ai notes that electroCore's Q1 2026 results demonstrate continued growth in the bioelectronic medicine sector, particularly within government healthcare channels like the VA. The company's strategy of expanding its product lines (gammaCore, Quell) and consumer brands (Truvaga) while exploring new indications aligns with broader industry trends towards non-invasive therapeutic devices.

Comparison to Industry Standards

• The reported gross profit margin of 87% is exceptionally high for a medical device company, often exceeding industry averages which can range from 40-70%.
• The 43% year-over-year revenue growth is robust, outperforming many established medical device companies that typically see single-digit to low-double-digit growth.
• The Adjusted EBITDA net loss improvement of 24% indicates progress towards profitability, a key metric watched by investors in growth-stage medical technology firms.
• The ROAS of 2.37x for Truvaga suggests efficient marketing spend compared to some direct-to-consumer health products where ROAS can be lower or more variable.

Management Changes

Legal Proceedings

• Legal fees related to ongoing litigation are impacting general and administrative expenses.

Stakeholder Impact

• Shareholders: Reaffirmed guidance and record revenue are positive indicators, but the increased net loss and reduced cash position may raise concerns about future funding needs and profitability.
• Employees: The addition of a COO and focus on scaling commercial operations suggest potential for growth and new opportunities.
• Creditors: The increased liabilities and reduced cash position could impact the company's ability to service debt in the short term.
• Suppliers: Increased sales volume may lead to higher demand for raw materials and components.

Next Steps

• Launch Quell Relief for lower extremity pain in the second half of 2026.
• Develop a next-generation mobile application to complement Truvaga and Quell.
• Continue to expand Truvaga internationally.
• Continue to enroll participants in the PTSD clinical study.
• Continue to grow prescription gammaCore sales within the VA.
• Continue to grow Quell Fibromyalgia sales.

Key Dates

Recommendation

The company shows strong revenue growth and operational improvements, but the increasing net loss, reduced cash balance, and mention of potential going concern issues warrant a cautious 'hold' rating until further clarity on funding and profitability is achieved.

Keywords

electroCore, 8-K, Q1 2026, Financial Results, Bioelectronic Technology, gammaCore, Truvaga, Quell